JP2015512860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512860A5 JP2015512860A5 JP2014542523A JP2014542523A JP2015512860A5 JP 2015512860 A5 JP2015512860 A5 JP 2015512860A5 JP 2014542523 A JP2014542523 A JP 2014542523A JP 2014542523 A JP2014542523 A JP 2014542523A JP 2015512860 A5 JP2015512860 A5 JP 2015512860A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound according
- pharmaceutically acceptable
- acceptable salt
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 13
- 208000005176 Hepatitis C Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 6
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- 239000002777 nucleoside Substances 0.000 description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 3
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 3
- -1 cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopropyloxycarbonylamino Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 description 1
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 description 1
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229950003954 isatoribine Drugs 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical group N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 1
- 229950006081 taribavirin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161560654P | 2011-11-16 | 2011-11-16 | |
| US61/560,654 | 2011-11-16 | ||
| PCT/US2012/065681 WO2013075029A1 (en) | 2011-11-16 | 2012-11-16 | Condensed imidazolylimidazoles as antiviral compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016171840A Division JP2016199593A (ja) | 2011-11-16 | 2016-09-02 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512860A JP2015512860A (ja) | 2015-04-30 |
| JP2015512860A5 true JP2015512860A5 (enExample) | 2015-10-29 |
| JP6082749B2 JP6082749B2 (ja) | 2017-02-15 |
Family
ID=47324426
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542523A Active JP6082749B2 (ja) | 2011-11-16 | 2012-11-16 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| JP2016171840A Withdrawn JP2016199593A (ja) | 2011-11-16 | 2016-09-02 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| JP2017220056A Withdrawn JP2018024705A (ja) | 2011-11-16 | 2017-11-15 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| JP2019166343A Ceased JP2019206597A (ja) | 2011-11-16 | 2019-09-12 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| JP2020169195A Withdrawn JP2021001230A (ja) | 2011-11-16 | 2020-10-06 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016171840A Withdrawn JP2016199593A (ja) | 2011-11-16 | 2016-09-02 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| JP2017220056A Withdrawn JP2018024705A (ja) | 2011-11-16 | 2017-11-15 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| JP2019166343A Ceased JP2019206597A (ja) | 2011-11-16 | 2019-09-12 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| JP2020169195A Withdrawn JP2021001230A (ja) | 2011-11-16 | 2020-10-06 | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
Country Status (36)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345658A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| ES2758726T3 (es) | 2009-05-13 | 2020-05-06 | Gilead Pharmasset Llc | Compuestos antivirales |
| AU2011328980B2 (en) | 2010-11-17 | 2015-07-30 | Gilead Sciences, Inc. | Antiviral compounds |
| BR112014000563A2 (pt) | 2011-07-09 | 2019-12-10 | Sunshine Lake Pharma Co., Ltd | composto, composição farmacêutica, e, uso do composto |
| DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
| WO2013075029A1 (en) * | 2011-11-16 | 2013-05-23 | Gilead Sciences, Inc. | Condensed imidazolylimidazoles as antiviral compounds |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| CN105121428B (zh) | 2013-02-07 | 2019-12-24 | 九州有机光材股份有限公司 | 具有二氮杂苯并菲环结构的化合物和有机电致发光器件 |
| US20140343008A1 (en) * | 2013-05-16 | 2014-11-20 | Gilead Pharmasset Llc | Hepatitis c treatment |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP6333372B2 (ja) * | 2013-07-09 | 2018-05-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤の組み合わせ |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
| US9562058B2 (en) | 2013-12-23 | 2017-02-07 | Gilead Sciences, Inc. | Crystalline forms of an antiviral compound |
| TW202014413A (zh) * | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| SMT202100592T1 (it) | 2014-12-26 | 2021-11-12 | Univ Emory | Derivati antivirali della n4-idrossicitidina |
| CN105801462A (zh) * | 2014-12-29 | 2016-07-27 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法 |
| CN104586802B (zh) * | 2015-02-02 | 2018-01-16 | 长春海悦药业股份有限公司 | 一种含有索菲布韦的药物组合物 |
| CN106008552B (zh) * | 2015-03-01 | 2020-08-21 | 南京圣和药业股份有限公司 | 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US10487067B2 (en) * | 2015-10-08 | 2019-11-26 | Mylan Laboratories Limited | Process for the preparation of velpatasvir |
| CN105294713A (zh) * | 2015-10-09 | 2016-02-03 | 重庆康施恩化工有限公司 | Velpatasvir中间体及其制备方法 |
| CN105801553B (zh) * | 2016-04-12 | 2018-06-19 | 爱斯特（成都）生物制药股份有限公司 | 一种苯并色烯衍生物的制备方法 |
| CN106916134B (zh) * | 2016-04-14 | 2020-04-17 | 苏州楚凯药业有限公司 | 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法 |
| WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
| WO2017191546A1 (en) * | 2016-05-05 | 2017-11-09 | Laurus Labs Private Ltd. | Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| MA45088A (fr) | 2016-05-27 | 2019-04-10 | Gilead Sciences Inc | Méthodes pour traiter des infections par le virus de l'hépatite b au moyen d'inhibiteurs de ns5a, ns5b ou ns3 |
| BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
| WO2018006811A1 (zh) * | 2016-07-08 | 2018-01-11 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的咪唑基化合物及其药物组合物 |
| KR101887969B1 (ko) * | 2016-08-30 | 2018-08-13 | 한국과학기술연구원 | 항바이러스 활성을 가지는 카르바졸 화합물 |
| CN107674064B (zh) * | 2016-11-30 | 2020-03-27 | 上海博志研新药物技术有限公司 | 维帕他韦中间体、制备方法及维帕他韦的制备方法 |
| CN106831737B (zh) * | 2017-02-27 | 2020-03-17 | 上海众强药业有限公司 | 维帕他韦及其衍生物的制备 |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN107501280A (zh) * | 2017-09-05 | 2017-12-22 | 安徽华昌高科药业有限公司 | 一种维帕他韦的合成方法 |
| CN107655986B (zh) * | 2017-09-08 | 2020-11-03 | 安徽一灵药业有限公司 | 一种维帕他韦有关物质的检测方法 |
| US10849960B2 (en) | 2017-09-08 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer |
| KR20240011880A (ko) | 2017-12-07 | 2024-01-26 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| CN108276421B (zh) * | 2018-02-13 | 2019-08-06 | 浙江永太药业有限公司 | 一种维帕他韦的合成方法 |
| US11865108B2 (en) | 2019-10-18 | 2024-01-09 | Wockhardt Limited | Nitrogen containing bicyclic compounds |
| CN111018870B (zh) * | 2019-11-29 | 2021-07-23 | 南京正济医药研究有限公司 | 一种维帕他韦中间体的制备方法 |
| CN110981879B (zh) * | 2019-12-09 | 2021-03-05 | 南通常佑药业科技有限公司 | 一种制备ns5a抑制剂-维帕他韦的方法 |
| CN113072615B (zh) * | 2021-03-24 | 2023-01-10 | 上海法默生物科技有限公司 | 一种维帕他韦中间体的制备方法 |
| JP7725617B2 (ja) * | 2021-05-21 | 2025-08-19 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
| WO2022246072A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| KR20240022574A (ko) | 2021-06-17 | 2024-02-20 | 아테아 파마슈티컬즈, 인크. | 유리한 항-hcv 조합 요법 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
| ATE167679T1 (de) | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| EP1411928A1 (en) | 2001-07-20 | 2004-04-28 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| ES2456702T3 (es) | 2003-05-09 | 2014-04-23 | Boehringer Ingelheim International Gmbh | Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C |
| US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| NZ552405A (en) | 2004-07-16 | 2011-04-29 | Gilead Sciences Inc | Pyrrolidine containing antiviral compounds |
| US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN101594863B (zh) | 2006-12-07 | 2011-12-07 | 第一三共株式会社 | 具有改进稳定性的涂膜制剂 |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2009102622A2 (en) * | 2008-02-11 | 2009-08-20 | Qualcomm Mems Technologies, Inc. | Methods for measurement and characterization of interferometric modulators |
| EP2250163B1 (en) | 2008-02-12 | 2012-03-28 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2010008863A (es) | 2008-02-13 | 2010-09-07 | Bristol Myers Squibb Co | Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c. |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| KR20110098779A (ko) | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Ｈｃｖ ｎｓ5ａ의 억제제 |
| CA2753313A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| RU2544010C2 (ru) | 2009-02-27 | 2015-03-10 | Энанта Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
| KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| CA2760205A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| ES2758726T3 (es) | 2009-05-13 | 2020-05-06 | Gilead Pharmasset Llc | Compuestos antivirales |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG178952A1 (en) * | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2503881B1 (en) * | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| CA2785488A1 (en) * | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| CN102918049A (zh) | 2010-03-09 | 2013-02-06 | 默沙东公司 | 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法 |
| US9125904B1 (en) | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| WO2012027712A2 (en) | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| AU2011328980B2 (en) * | 2010-11-17 | 2015-07-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| WO2013075029A1 (en) | 2011-11-16 | 2013-05-23 | Gilead Sciences, Inc. | Condensed imidazolylimidazoles as antiviral compounds |
| EP2907505A3 (en) | 2011-12-29 | 2015-12-30 | Abbvie Inc. | Solid compositions comprising an HCV inhibitor |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
-
2012
- 2012-11-16 WO PCT/US2012/065681 patent/WO2013075029A1/en not_active Ceased
- 2012-11-16 DK DK12798525.7T patent/DK2635588T3/en active
- 2012-11-16 UA UAA201507807A patent/UA119437C2/uk unknown
- 2012-11-16 ES ES12798525.7T patent/ES2544107T3/es active Active
- 2012-11-16 EA EA201591244A patent/EA030941B1/ru unknown
- 2012-11-16 SG SG10201700947UA patent/SG10201700947UA/en unknown
- 2012-11-16 MX MX2013005575A patent/MX346729B/es active IP Right Grant
- 2012-11-16 EA EA201890333A patent/EA037883B1/ru unknown
- 2012-11-16 MY MYPI2014001415A patent/MY173045A/en unknown
- 2012-11-16 KR KR1020187023418A patent/KR102036469B1/ko active Active
- 2012-11-16 SI SI201231853T patent/SI3431477T1/sl unknown
- 2012-11-16 KR KR1020137015198A patent/KR101890400B1/ko active Active
- 2012-11-16 PL PL18175400T patent/PL3431477T3/pl unknown
- 2012-11-16 MX MX2018015604A patent/MX377552B/es unknown
- 2012-11-16 AP AP2013006877A patent/AP2013006877A0/xx unknown
- 2012-11-16 SI SI201231367T patent/SI2907816T1/sl unknown
- 2012-11-16 PH PH1/2013/500976A patent/PH12013500976A1/en unknown
- 2012-11-16 ES ES18175400T patent/ES2843023T3/es active Active
- 2012-11-16 EA EA202190619A patent/EA202190619A1/ru unknown
- 2012-11-16 HU HUE12798525A patent/HUE027733T2/en unknown
- 2012-11-16 PL PL12798525T patent/PL2635588T3/pl unknown
- 2012-11-16 EP EP15156617.1A patent/EP2907816B1/en active Active
- 2012-11-16 LT LTEP15156617.1T patent/LT2907816T/lt unknown
- 2012-11-16 US US13/679,862 patent/US20130164260A1/en not_active Abandoned
- 2012-11-16 KR KR1020197030548A patent/KR20190121406A/ko not_active Ceased
- 2012-11-16 CN CN201610126299.4A patent/CN105837584B/zh active Active
- 2012-11-16 ES ES15156617.1T patent/ES2687291T3/es active Active
- 2012-11-16 EP EP20194823.9A patent/EP3778606A3/en not_active Withdrawn
- 2012-11-16 PT PT15156617T patent/PT2907816T/pt unknown
- 2012-11-16 MD MDA20130029A patent/MD4403C1/ro active IP Right Grant
- 2012-11-16 SI SI201230240T patent/SI2635588T1/sl unknown
- 2012-11-16 AU AU2012318253A patent/AU2012318253B8/en active Active
- 2012-11-16 EP EP18175400.3A patent/EP3431477B1/en active Active
- 2012-11-16 JP JP2014542523A patent/JP6082749B2/ja active Active
- 2012-11-16 SM SM20180470T patent/SMT201800470T1/it unknown
- 2012-11-16 DK DK15156617.1T patent/DK2907816T3/en active
- 2012-11-16 ME MEP-2015-132A patent/ME02196B/me unknown
- 2012-11-16 EP EP12798525.7A patent/EP2635588B1/en active Active
- 2012-11-16 KR KR1020207027928A patent/KR102241651B1/ko active Active
- 2012-11-16 CA CA2815082A patent/CA2815082C/en active Active
- 2012-11-16 HU HUE15156617A patent/HUE039966T2/hu unknown
- 2012-11-16 PE PE2013001207A patent/PE20141163A1/es active IP Right Grant
- 2012-11-16 RS RS20150571A patent/RS54207B1/sr unknown
- 2012-11-16 MD MDA20150091A patent/MD4521C1/ro active IP Right Grant
- 2012-11-16 MX MX2017004156A patent/MX361735B/es unknown
- 2012-11-16 KR KR1020217010778A patent/KR20210043734A/ko not_active Ceased
- 2012-11-16 BR BR112013012091A patent/BR112013012091A2/pt not_active Application Discontinuation
- 2012-11-16 CN CN201280004097.2A patent/CN103328480B/zh active Active
- 2012-11-16 PL PL15156617T patent/PL2907816T3/pl unknown
- 2012-11-16 EA EA201390576A patent/EA023644B1/ru active Protection Beyond IP Right Term
- 2012-11-16 US US13/679,874 patent/US8940718B2/en active Active
- 2012-11-16 RS RS20181062A patent/RS57638B1/sr unknown
- 2012-11-16 PT PT127985257T patent/PT2635588E/pt unknown
- 2012-11-16 PE PE2017001319A patent/PE20171444A1/es unknown
- 2012-11-16 UA UAA201306068A patent/UA110354C2/uk unknown
- 2012-11-16 HR HRP20150725TT patent/HRP20150725T1/hr unknown
- 2012-11-16 CA CA 2884712 patent/CA2884712A1/en not_active Abandoned
- 2012-11-16 PT PT181754003T patent/PT3431477T/pt unknown
-
2013
- 2013-03-01 US US13/783,056 patent/US8575135B2/en active Active
- 2013-05-13 IL IL226345A patent/IL226345A/en active IP Right Grant
- 2013-05-17 CL CL2013001428A patent/CL2013001428A1/es unknown
- 2013-05-17 CR CR20130231A patent/CR20130231A/es unknown
- 2013-05-17 MX MX2020010330A patent/MX2020010330A/es unknown
- 2013-05-17 CO CO13122291A patent/CO6791562A2/es active IP Right Grant
- 2013-06-10 MA MA36000A patent/MA34727B1/fr unknown
- 2013-07-25 EC ECSP13012790 patent/ECSP13012790A/es unknown
- 2013-10-08 US US14/049,133 patent/US8921341B2/en active Active
-
2014
- 2014-04-24 US US14/261,325 patent/US9051340B2/en active Active
- 2014-11-13 US US14/541,057 patent/US9868745B2/en active Active
-
2015
- 2015-04-24 US US14/696,233 patent/US9221833B2/en active Active
- 2015-08-13 SM SM201500197T patent/SMT201500197B/xx unknown
- 2015-09-09 CY CY20151100779T patent/CY1116987T1/el unknown
- 2015-11-23 US US14/949,756 patent/US20160083394A1/en not_active Abandoned
- 2015-12-21 PH PH12015502839A patent/PH12015502839B1/en unknown
-
2016
- 2016-02-15 IL IL244124A patent/IL244124A0/en unknown
- 2016-02-15 IL IL244123A patent/IL244123A0/en unknown
- 2016-02-15 IL IL244122A patent/IL244122A0/en unknown
- 2016-07-11 US US15/207,415 patent/US9809600B2/en active Active
- 2016-09-02 JP JP2016171840A patent/JP2016199593A/ja not_active Withdrawn
-
2017
- 2017-05-17 IL IL252345A patent/IL252345B/en unknown
- 2017-10-04 US US15/725,193 patent/US20180244683A1/en not_active Abandoned
- 2017-11-15 JP JP2017220056A patent/JP2018024705A/ja not_active Withdrawn
- 2017-11-30 US US15/828,377 patent/US20180186806A1/en not_active Abandoned
-
2018
- 2018-06-27 EC ECSENADI201848718A patent/ECSP18048718A/es unknown
- 2018-08-29 HR HRP20181384TT patent/HRP20181384T1/hr unknown
- 2018-09-12 CY CY20181100945T patent/CY1121225T1/el unknown
- 2018-10-11 US US16/158,204 patent/US10807990B2/en active Active
-
2019
- 2019-02-14 MY MYPI2019000563A patent/MY201670A/en unknown
- 2019-04-08 US US16/378,089 patent/US20200071337A1/en not_active Abandoned
- 2019-09-12 JP JP2019166343A patent/JP2019206597A/ja not_active Ceased
-
2020
- 2020-07-24 US US16/938,767 patent/US20210053981A1/en not_active Abandoned
- 2020-10-06 JP JP2020169195A patent/JP2021001230A/ja not_active Withdrawn